肠黏膜屏障:中药治疗心血管疾病的潜在靶点
本文综述中药(中药植物药代谢物、中药复方及中成药)通过修复肠黏膜屏障治疗心血管疾病的研究及潜在机制。中药可调节肠道菌群结构与代谢物、增强肠紧密连接、改善肠道运动障碍、修复肠道组织形态、保护肠道血管屏障完整性,并抑制心肌纤维化与肥大、促进血管修复。
要点
- 肠黏膜屏障损伤是心血管疾病的重要病理改变并加速疾病进展。
- 中药通过抗炎、抗氧化、抗凋亡修复肠黏膜屏障并调节糖脂代谢。
- 中药多成分多靶点特性使其成为心血管疾病治疗的重要调节剂。
核心结论
- 肠黏膜屏障是中药治疗心血管疾病的潜在靶点,中药通过修复该屏障发挥心血管保护作用。
研究设计与样本
- 本文为综述,汇总中药(中药植物药代谢物、中药复方及中成药)靶向修复肠黏膜屏障治疗心血管疾病的相关研究及潜在机制。
主要发现
- 中药可调节肠道菌群结构与代谢物。
- 中药增强肠紧密连接、改善肠道运动障碍、修复肠道组织形态。
- 中药通过抗炎、抗氧化、抗凋亡保护肠道血管屏障完整性。
- 中药抑制心肌纤维化与肥大并促进血管修复。
- 中药影响肠黏膜屏障并调节糖脂代谢,高脂血症、肥胖和糖尿病与心血管疾病密切相关。
临床怎么用
- 临床可关注心血管疾病患者的肠黏膜屏障状态,将其作为中药干预的潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiovascular disease (CVD) is a serious public health problem, and among non-communicable diseases, CVD is now the leading cause of mortality and morbidity worldwide. CVD involves multiple organs throughout the body, especially the intestinal tract is the first to be involved. The impairment of the intestinal mucosal barrier is considered a significant pathological alteration in CVD and also contributes to the accelerated progression of the disease, thereby offering novel insights for CVD prevention and treatment. The treatment of Chinese medicine is characterized by multi-metabolites, multi-pathways, and multi-targets. In recent years, the studies of Traditional Chinese Medicine (TCM) in treating CVD by repairing the intestinal mucosal barrier have gradually increased, showing great therapeutic potential. This review summarizes the studies related to the treatment of CVD by TCM (metabolites of Chinese botanical drugs, TCM formulas, and Chinese patent medicine) targeting the repair of the intestinal mucosal barrier, as well as the potential mechanisms. We have observed that TCM exerts regulatory effects on the structure and metabolites of gut microbiota, enhances intestinal tight junctions, improves intestinal dyskinesia, repairs intestinal tissue morphology, and preserves the integrity of the intestinal vascular barrier through its anti-inflammatory, antioxidant, and anti-apoptotic properties. These multifaceted attributes position TCM as a pivotal modulator of inhibiting myocardial fibrosis, and hypertrophy, and promoting vascular repairment. Moreover, there exists a close association between cardiovascular risk factors such as hyperlipidemia, obesity, and diabetes mellitus with CVD. We also explore the mechanisms through which Chinese botanical drugs impact the intestinal mucosal barrier and regulate glucose and lipid metabolism. Consequently, these findings present novel insights and methodologies for treating CVD.
引用
- Liu J, Wei X, Wang T, et al. Intestinal mucosal barrier: a potential target for traditional Chinese medicine in the treatment of cardiovascular diseases. Front Pharmacol. 2024. PMID: 38469405. doi:10.3389/fphar.2024.1372766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。